Latest Breaking News On - Tyvaso - Page 7 : vimarsana.com

United Therapeutics Corporation (Nasdaq: UTHR) announced today that the first patient has enrolled in the phase 3 TETON study, which is expected to evaluate approximately 396 adult patients with idiopathic pulmonary fibrosis (IPF). This 52-week study will evaluate the impact of Tyvaso on a key prognostic indicator for IPF known as forced vital capacity (FVC). IPF is a progressive lung disease characterized by the loss of the ability of the lungs to absorb oxygen, ultimately resulting in respirat

United therapeuticsIdiopathic pulmonary fibrosisPulmonary hypertensionFood and drug administrationUnited therapeuticsUnited therapeutics corporationInterstitial lung diseaseUng diseaseஒன்றுபட்டது சிகிச்சை